Start Free Trial

PERSONALIZED DRUG RESPONSE: IMPLEMENTATION and EVALUATION in CKD

Horizon Europe Guarantee · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$365,361
Est. Value
Active
Status

Opportunity Overview

Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable. Currently there are no validated pharmacodynamic biomarkers in CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice. Thus, there is an urgent need to validate and translate biomarkers as tools for daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recently discovered pharmacodynamic biomarkers for CKD treatment, and has access to a vast amount of clinical data, bio-samples. PRIME CKD will: 1) Provide a breakthrough in the pharmacotherapy of CKD with the validation and implementation of pharmacodynamic biomarkers which will advance personalized medicine. 2) Scientifically validate innovative clinical trial elements, pipelines and qualification procedures that can be used by researchers, diagnostics industries and regulatory authorities. 3) Establish a Stakeholder Network to truly engage patients, clinicians and other stakeholders in implementation of personalized medicines 4) Develop a roadmap for biomarker use in daily clinical practice for the optimal treatment of CKD. These results will enable clinicians to match patients with CKD with the most effective available drug within the shortest possible timeframe leading to less disease burden and progression of disease, enhanced quality of life and increased cost-efficiency. PRIME-CKD results will thus unlock the potential of biomarkers in healthcare and close the gap between biomarker research and clinical use in daily practice

This is one of 21 active United Kingdom Monitoring Evaluation opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHorizon Europe Guarantee
CountryUnited Kingdom
CategoryMonitoring Evaluation
Estimated value$365,361
Response dueNot specified / rolling
StatusActive - open for responses
Official sourceView original notice

Related Opportunities in United Kingdom

Fire System Monitoring
Intellipig: An automated on-farm pig health monitoring system
Terpomet – Real-time monitoring-led optimisation of plant cell culture-based terpenoid biomanufacturing
Strategies For The Evaluation And Assessment Of Ocean Based Carbon DioxideRemoval (SEAO2-CDR)
Counterfactual Assessment and Valuation for Awareness Architecture
AMBROSIA: Autonomous Monitoring of Biodiversity with Remote Ocean Sensing and Integrated Analytics
Fast and accurate self-monitoring tests for better adherence to exercise and diet
Meaningful Product Lifecycles - data-driven methods for assessment and communication

See every United Kingdom Monitoring Evaluation opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →